Investor's Business Daily on MSN17h
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.
Immunovant and Roivant Sciences said Wednesday that their rare disease drug succeeded in a final-phase study, but the duo won't seek regulatory approval for it.Please watch the video at Investors.com ...
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data
Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...
The Pharma Letter23h
Positive batoclimab data from Immunovant, but doubts raised on further development
Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...